Related Experiment Video
Updated: Jan 11, 2026
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
A masking clamp for conditional activation of therapeutic antibodies
Adrian Bloch1, Jan Felix Zimmermann1, Jan Habermann2,3
1Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany.
Abstract:
Therapeutic monoclonal antibodies (mAbs) constitute cornerstone therapeutics in oncology, yet their clinical utility is often limited by on-target, off-tumor toxicity due to shared antigen expression in both tumor and healthy tissues. To counteract this issue, various approaches, including pH-dependent, as well as affinity-based and steric hindrance-based masked antibodies, have been developed. Several steric hindrance-based masking strategies have been proposed utilizing non-human proteins, potentially leading to an immunogenic response. To address this challenge, we engineered a modular protein-based masking platform leveraging the high-affinity interaction between human calmodulin (CaM) and a calmodulin-binding peptide (CBP). This strategy enables conditional activation of antibodies via tumor microenvironment (TME)-associated proteases (e.g., MMP-9), minimizing systemic off-tumor binding. The CaM-CBP peptide clamp, composed exclusively of human-derived protein domains, was fused to the amino termini of heavy and light chains of trastuzumab and cetuximab. On-cell binding assays demonstrated up to a 410-fold reduction in EC50 for masked constructs across multiple antigen-antibody systems. Functional validation using a reporter-cell-based antibody-dependent cellular cytotoxicity (ADCC) assay confirmed that masking abrogated effector cell activation, leading to up to 78-fold reduction of EC50 and no ADCC activation at concentrations corresponding to the onset of maximal ADCC activation by unmodified antibodies. Demasking via MMP-9-mediated linker hydrolysis restored antigen binding and ADCC potency. Structural optimization revealed that linker length and clamp positioning critically influenced masking efficiency. This human-derived, modular masking platform mitigates immunogenicity risks while enabling tumor-selective antibody activation. Its adaptability across antibody scaffolds underscores broad applicability for improving the therapeutic index of antibodies.
Insights
Engineered a human-derived antibody masking platform using calmodulin and a binding peptide to reduce off-tumor toxicity. This modular system allows tumor-specific activation, enhancing safety and efficacy for cancer therapies.
Area of Science:
- Biotechnology
- Oncology
- Protein Engineering
Background:
- Therapeutic monoclonal antibodies (mAbs) are crucial in oncology but face limitations due to on-target, off-tumor toxicity from shared antigen expression.
- Existing masking strategies often use non-human proteins, risking immunogenicity.
- A need exists for safer, tumor-selective antibody activation methods.
Purpose of the Study:
- To develop a novel, human-derived, modular masking platform for therapeutic antibodies.
- To enable conditional antibody activation via tumor microenvironment (TME)-specific proteases.
- To mitigate off-tumor binding and reduce immunogenicity risks.
Main Methods:
- Engineered a modular protein-based mask using human calmodulin (CaM) and a calmodulin-binding peptide (CBP).
- Fused the CaM-CBP clamp to trastuzumab and cetuximab heavy and light chains.
- Assessed on-cell binding, antibody-dependent cellular cytotoxicity (ADCC) in reporter-cell assays, and de-masking via MMP-9.
- Optimized linker length and clamp positioning for masking efficiency.
Main Results:
- Masked antibody constructs showed up to a 410-fold reduction in EC50 for antigen binding.
- Masking abrogated effector cell activation, with up to a 78-fold reduction in EC50 for ADCC.
- MMP-9-mediated de-masking restored antigen binding and ADCC potency.
- Human-derived platform demonstrated reduced immunogenicity potential.
Conclusions:
- The CaM-CBP masking platform enables tumor-selective antibody activation by leveraging TME proteases.
- This human-derived system effectively reduces on-target, off-tumor toxicity and potential immunogenicity.
- The modular and adaptable nature of the platform suggests broad applicability for enhancing antibody therapeutics.
